160 East 53rd StreetNew York, NY 10022
Overview of Dr. Harding
Dr. Harding is a board-certified medical oncologist and NCI/R01 funded clinical scientist who specializes in caring for people with liver cancer, gallbladder cancer, and bile duct cancer, as well as other gastrointestinal cancers. He completed his internal medicine residency at New York Presbyterian Hospital and Medical Oncology and Hematology Fellowship at Memorial Sloan Kettering Cancer Center. In 2013, he was recruited to the Gastrointestinal Oncology and Early Drug Development Services at Memorial Sloan Kettering Cancer Center. Dr. Harding is nationally and internationally known for his research in developing new therapies for difficult to treat cancers and has co-led or supported the FDA approvals of several drugs used to treat people with liver and bile duct cancer. He has published over 300 peer-reviewed manuscripts or abstracts focusing on the biology and treatment of gastrointestinal cancers, notably prestigious journals such as the New England Journal of Medicine, Lancet Oncology, Journal of Clinical Oncology, JAMA Oncology, Nature, Cell, and Cancer Discovery. He serves on national and international cancer guideline committees, including the American Society of Clinical Oncology guidelines, making recommendations on how liver and bile duct cancers should be treated. His research and training have been supported by competitive grants from the American Society of Clinical Oncology, the National Comprehensive Cancer Network, the American Association for Cancer Research, the Howard Hughes Medical Institute, and the National Institutes of Health. Dr. Harding is also focused on improving how we conduct clinical research with patients and increasing access to clinical trials. He is an Associate Chair of the Institutional Review Board, which is the committee that approves all clinical research at Memorial Sloan Kettering and is also part of several other executive committees aimed at improving the conduct of clinical trials.
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2010 - 2013
New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 2007 - 2010
Albert Einstein College of MedicineClass of 2007
Certifications & Licensure
NY State Medical License 2008 - 2028
NJ State Medical License 2019 - 2027
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification Sunrise Ambulatory Care, Allscripts, 2016-2017
- CMS Meaningful Use Stage 1 Certification MyMSK, Memorial Sloan Kettering, 2016-2017
Clinical Trials
- A Study of LY2157299 in Participants With Hepatocellular Carcinoma Start of enrollment: 2011 Mar 30
- Study of the Glutaminase Inhibitor CB-839 in Solid Tumors Start of enrollment: 2014 Feb 01
- A Study of Emibetuzumab in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer Start of enrollment: 2014 Mar 07
Publications & Presentations
PubMed
- Pembrolizumab and olaparib in homologous-recombination-deficient metastatic pancreatic cancer: the phase 2 POLAR trial.Wungki Park, Catherine A O'Connor, Joanne F Chou, Marc Hilmi, Zeynep Tarcan
Nature Medicine. 2026-03-25 - Outcomes of First Versus Second-Line Hepatic Artery Infusion Chemotherapy in Unresectable Intrahepatic Cholangiocarcinoma.Naaz Nasar, Misha Armstrong, Joanne F Chou, Mithat Gonen, Kevin C Soares
Annals of Surgical Oncology. 2026-03-01 - ASO Visual Abstract: Outcomes of First-versus Second-Line Hepatic Artery Infusion Chemotherapy in Unresectable Intrahepatic Cholangiocarcinoma.Naaz Nasar, Misha Armstrong, Joanne F Chou, Mithat Gonen, Kevin C Soares
Annals of Surgical Oncology. 2026-03-01
Lectures
- Nivolumab (NIVO) and drug eluting bead transarterial chemoembolization (deb-TACE): Preliminary results from a phase I study of patients (pts) with liver limited hepato...ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/24/2020
- A phase II randomized placebo-controlled study investigating the combination of yiv-906 and sorafenib (SORA) in HBV (+) patients (Pts) with advanced hepatocellular car...ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/24/2020
- ADI-PEG 20 and FOLFOX6: A phase 1 study in pts (pts) with advanced hepatocellular carcinoma (HCC).2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
Press Mentions
Routine Prenatal Test Discovers Woman's Rare, Aggressive Cancer at Age 35December 12th, 2025
FDA Approves Zanidatamab for Biliary Tract CancerNovember 21st, 2024- Treatment Options for Advanced HCC Patients Who Are Not Eligible for IO First LineMarch 14th, 2023
Grant Support
- HER2 PET imaging to assess HER2 heterogeneity and predict response to HER2-targeted therapy in biliary tract cancerThe National Institutes of Health / National Cancer Institute2026–2031
- Rapid Target Identification and Preclinical Antitumor Validation of Antibody Drug Conjugate Therapy in Biliary Tract CancersSociety of MSKCC2024–2025
- Improving Outcome in Patients with Advanced Intrahepatic Cholangiocarcinoma: A Randomized Phase II Study of Gemcitabine and Oxaliplatin With or Without Regional FloxuridineNational Institutes of Health / National Cancer Institute2020–2025
- ID Protein Degradation as a Therapeutic Strategy for Hepatobiliary Cancer and Other Solid TumorsExperimental Therapeutics Center2022–2024
- Implementation of a Liquid Biopsy to Enrich Responses to Immunotherapy in Patients with Advanced Liver CancerSociety of MSKCC2019–2020
Professional Memberships
- Member
- Member
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
